However, for advanced metastatic melanoma, only modest results are obtained with DTIC (1975), recombinant interferon α-2b (1995), and high-dose interleukin 2 (HD IL-2) (1998), the only three conventional therapeutic agents approved by the Food and Drug Administration (FDA) for metastatic melanoma. Here, IL2 is linked to metastatic melanoma.